関連する実験動画

Updated: May 5, 2026

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Published on: April 3, 2017

アポリポプロテインE欠乏マウスの動脈硬化に対するマクロファージ12/15-リポキシゲナーズの重要な役割

Yuqing Huo¹, Lei Zhao, Matthew Craig Hyman

¹University of Virginia, Charlottesville, Va, USA. Yuqing@umn.edu.

|September 29, 2004

まとめ

マクロファージ12/15-リポキシゲナーゼ (12/15-LO) は,動脈硬化症の発達に重要な役割を果たしています. マクロファージにおけるその欠如は,内皮炎症と泡細胞形成を制限することによって,動脈硬化症を軽減します.

科学分野:

心血管科学の研究について
脂質代謝についてです.
炎症生物学炎症生物学とは

背景:

白血球型12/15-リポキシゲナーゼ (12/15-LO) 欠乏症は,マウスモデルにおける動脈硬化症を減少させます.
12/15-LOは,マクロファージ,血管細胞,アディポサイトを含む様々な細胞で発現します.

研究の目的:

動脈硬化症の発症を誘発する12/15-LOの特定の細胞源を特定する.

主な方法:

骨髄移植の実験は12/15-LO-/-/apoE-/-とapoE-/-のマウスで行われました.
内皮活性化および泡細胞形成の測定は,野生型および12/15-LO-/-マウスからのマクロファージを使用して行われました.

主要な成果:

12/15-LO欠乏症の骨髄細胞はアテロスクレロシスからApoE-/-マウスを有意に保護しました.
12/15-LOが欠けているマクロファージは,LDLへの反応として,内皮の活性化と泡細胞形成が低下した.
骨髄細胞における12/15-LOの欠如は,動脈硬化性病変の重度の低下につながった.

結論:

マクロファージに由来する12/15-LOは,動脈硬化を促進する上で重要な役割を果たします.
マクロファージにおける12/15-LOは,内皮の炎症と泡細胞形成を誘導することによって,動脈硬化に寄与する.

さらに関連する動画

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

Quantification of Atherosclerosis in Mice

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

関連する概念動画

Inflammation

Inflammation

Lipid-derived Compounds in the Human Body

Lipid-derived Compounds in the Human Body

Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...